In this health technology assessment we have compared the relative effectiveness and cost-effectiveness of seven new drugs used for the treatment of advanced malignant melanoma patients in the Norwegian setting. The drugs are: cobimetinib, dabrafenib, ipilimumab, nivolumab, pembrolizumab, trametinib and vemurafenib.
http://ift.tt/2qp4Rfr
Πέμπτη 25 Μαΐου 2017
A Health Technology Assessment of the New Drugs for Inoperable or Metastatic Malignant Melanoma Patients [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου